Exogenous supplementation with LCAT also relieve liver fibrosis and increase BMD in the mouse HOD model by promoting the reversal of cholesterol transport from the bone to the liver via liver-bone axis. The gene discussed is LCAT; the disease is hypopigmentation, organomegaly, and delayed myelination and development.